GILD Shares Outstanding History
Below is a table of the GILD shares outstanding history going back to 2/19/2010:

Date GILD Shares Outstanding
2/19/20101.81B
4/30/20101.78B
7/30/20101.68B
10/29/20101.62B
2/18/20111.59B
4/29/20111.57B
7/29/20111.54B
10/28/20111.50B
2/10/20121.51B
4/27/20121.51B
7/20/20121.51B
10/26/20121.52B
1/28/20131.52B
2/15/20131.52B
4/26/20131.53B
7/19/20131.53B
10/18/20131.53B
2/14/20141.54B
4/25/2014535.68M
7/25/20141.51B
10/31/20141.51B
2/13/20151.49B
4/30/20151.47B
7/31/20151.47B
10/30/20151.44B
2/12/20161.37B
4/29/20161.33B
7/31/20161.32B
10/31/20161.32B
2/16/20171.31B
4/28/20171.31B
7/31/20171.31B
10/31/20171.31B
2/15/20181.31B
4/30/20181.30B
7/30/20181.30B
10/30/20181.29B
2/15/20191.28B
3/15/20191.27B
4/30/20191.27B
7/30/20191.27B
10/31/20191.27B

Also see: GILD Market Cap History
and GILD YTD Return
GILD Historical Shares Outstanding:
-3.61% CAGR
GILD Historical Shares Outstanding: +-3.61% CAGR

Mouse over chart for data details
2/19/2010 ...10/31/2019
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases. Co.'s products include Biktarvy for the treatment of HIV-1 infection in certain patients, Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease, Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and Letairis® (ambrisentan) for the treatment of pulmonary arterial hypertension. We show 42 historical shares outstanding datapoints in our coverage of GILD's shares outstanding history.

Understanding the changing numbers of GILD shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like GILD versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching GILD by allowing them to research GILD shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for GILD:
GILD SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Gilead Sciences (GILD) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

GKOS Shares Outstanding History
GLYC Shares Outstanding History
GMED Shares Outstanding History
GNCA Shares Outstanding History
GNMK Shares Outstanding History
GNMX Shares Outstanding History
GTHX Shares Outstanding History
GTS Shares Outstanding History
GTXI Shares Outstanding History
HAE Shares Outstanding History
More Healthcare companies »

 

GILD Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2019, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.